Results 211 to 220 of about 2,870,340 (221)

Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.

Current Medicinal Chemistry, 2017
L. Sakkas, A. Mavropoulos, D. Bogdanos
semanticscholar   +1 more source

Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.

Current pharmaceutical design, 2014
P. Heckman, C. Wouters, Jos Prickaerts
semanticscholar   +1 more source

The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction

Expert Opinion on Drug Safety, 2016
E. Ventimiglia, P. Capogrosso, F. Montorsi, A. Salonia   +3 more
semanticscholar   +1 more source

Phosphodiesterase 4 Inhibitors

2001
Christopher H. Compton, Graham Sturton, Meretta J. Marks, Theodore J. Torphy   +3 more
openaire   +2 more sources

Phosphodiesterase Inhibitors

2007
openaire   +2 more sources

Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.

Sexual Medicine Reviews, 2017
F. Yafi, I. Sharlip, E. Becher
semanticscholar   +1 more source

Phosphodiesterase Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

International Archives of Allergy and Immunology, 2014
C. Page
semanticscholar   +1 more source

Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.

Journal of the American Medical Association (JAMA), 2015
S. Loeb, Y. Folkvaljon, M. Lambe, D. Robinson, H. Garmo, C. Ingvar, P. Stattin   +6 more
semanticscholar   +1 more source

Theophylline and Phosphodiesterase Inhibitors

2005
openaire   +2 more sources

Theophylline and Phosphodiesterase Inhibitors

2014
Clive P. Page, Domenico Spina
openaire   +2 more sources